

Special Issue

Mechanisms and Novel Therapeutic Approaches for Gynecologic Cancer

Message from the Guest Editor

The number of patients who suffer gynecologic cancer, such as ovarian cancer and endometrial cancer, has been increasing worldwide. A possible cause of the high lethality of gynecologic cancer includes the lack of early detection tools and effective therapeutic interventions. In this regard, basic research on their pathophysiology and novel molecular-based therapeutic strategies is urgently required.

In this background, there will be a Special Issue of *Biomedicines* entitled “Mechanisms and Novel Therapeutic Approaches for Gynecologic Cancer” which will focus on how basic research such as genomics, epigenomics, and proteomics as well as clinical research can contribute to the improvement of the mortality of the gynecologic cancer patients. We would like to welcome basic and clinical research which can show us the possibility of the wide variety of therapeutic approaches for gynecological cancer. In addition to original articles, review articles describing recent interesting topics regarding gynecologic cancer are also welcomed.

Guest Editor

Dr. Naomi Nakayama

Department of General Medicine and Community Health Science,
School of Medicine, Hyogo Medical University, Hyogo 669-2321, Japan

Deadline for manuscript submissions

closed (30 September 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/65260

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).